Novartis Raises FullYear Sales and Profit Outlook Signaling Strong Operating Momentum Standard Chartered Plans to Reduce Corporate Functions Roles by Over 15 as Part of Efficiency Drive US Payrolls Jump More Than Expected But Report Signals Underlying Economic Red Flags AIDriven Drug Discovery Could Accelerate Treatments for Brain Conditions Like MND Okta Leverages AI Agents as IdentitySecurity Growth Driver Amid Stock Decline Nebius Group to Present at BofA Global Technology Conference Potential Catalyst for AIFocused Firm GGG Q1 2026 Earnings EPS Misses by 12 Shares Edge Higher VSCO Q1 2026 Earnings Earnings Surge Past Estimates Stock Reacts Positively Voyager Therapeutics Q1 2026 Earnings EPS Beat Masks Strategic Uncertainty as Stock Declines VRRM Q1 2026 Earnings EPS Beats Estimates on Strong Execution Stock Slightly Higher Champions Oncology Inc CSBR Q1 2026 Earnings EPS Falls Sharply Below Estimates Amid Challenging Quarter Under Armour UAA Q1 2026 Earnings EPS Misses Estimates Stock Rises Despite Loss VGM Advances 126 as Muni Bond Trust Nears Key Resistance at 1078 Blackrock MuniHoldings New Jersey Quality Fund MUJ Edges Higher Amid Steady Demand Ironwood Pharmaceuticals IRWD Edges Higher Amid Tight Trading Range ZK International Group ZKIN Drops 714 Key Levels Under Pressure Obsidian Energy OBE Slips 17 Amid Sector Pressure Holds Near Key Support Patagonias Trademark Lawsuit Against Drag Queen Pattie Gonia Highlights Brand Protection Challenges CLDX Q1 2026 Earnings Clinicalstage biotech reports widerthanexpected loss as pipeline investment continues Novanta Inc NOVT Rallies 225 as Stock Approaches Key Resistance Gabelli MultiMedia Trust GGT Holds Steady at 427 Amid Quiet Trading TAL Education Group TAL Holds Near Support After Modest Gain Pulsenmore Ltd PLSM Edges Higher as Stock Tests Key Resistance Levels CorMedix CRMD Rises 242 as Momentum Builds Toward Key Resistance MEGI Holds Steady Near Support as Infrastructure Megatrend Fund Sees Modest Decline Community Healthcare Trust CHCT Rises 104 Testing Key Resistance Near 1844 Rapport Therapeutics RAPP Hovers Near Support Tests Key Level After Mild Decline